ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "immunosuppressants"

  • Abstract Number: 1877 • 2018 ACR/ARHP Annual Meeting

    Specific Pneumoproteins Predict Progression of Interstitial Lung Disease in Systemic Sclerosis Patients Undergoing Treatment with Immunosuppression

    Elizabeth R. Volkmann1, Donald P. Tashkin1, Masataka Kuwana2, Ning Li3, Julio Charles4, Faye N. Hant5, Galina S. Bogatkevich6, Tanjina Akter6, Michael Roth7, Hyun J. Grace Kim8, Jonathan Goldin9, Dinesh Khanna10, Philip J. Clements11, Daniel E. Furst7, Robert Elashoff12, Rick Silver13 and Shervin Assassi14, 1University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 2Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 3Biomathematics, University of California, Los Angeles, Los Angeles, CA, 4University of Texas Health Science Center at Houston, Houston, TX, 5Rheumatology, Medical University of South Carolina, Charleston, SC, 6Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, 7Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 8Department of Radiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, 9Department of Radiological Sciences at UCLA, University of California, Los Angeles, David Geffen School of Medicine, Santa Monica, CA, 10Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, 11Medicine, University of California, Los Angeles, Los Angeles, CA, 12University of California, Los Angeles, Los Angeles, CA, 13Rheumatology, Medical University of SC, Charleston, SC, 14University of Texas McGovern Medical School, Houston, TX

    Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in systemic sclerosis (SSc). While some SSc-ILD patients are stable or improve with immunosuppressive…
  • Abstract Number: 1878 • 2018 ACR/ARHP Annual Meeting

    Immunosuppression in Diffuse Systemic Sclerosis Improves Outcomes Using a Novel Composite Response Index

    Boyang Zheng1, Mianbo Wang2 and Murray Baron3, 1Rheumatology, McGill University Health Center (MUHC), Montreal, QC, Canada, 2Lady Davis Institute for Medical Research, Montreal, QC, Canada, 3Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada

    Background/Purpose: Diffuse systemic sclerosis (dcSSc) is a devastating multi-organ disease where the mainstay of treatment is immunosuppression. Data on these therapies are mostly based on…
  • Abstract Number: 2269 • 2018 ACR/ARHP Annual Meeting

    Infliximab Therapy in Refractory Retinal Vasculitis of Behçet’s Disease, Short and Long-Term Follow-up. Multicenter Study of 72 Patients

    José Luis Martín-Varillas1, Belén Atienza-Mateo1, Vanesa Calvo-Río2, Diana Prieto Peña2, Monica Calderón Goercke2, Rosalía Demetrio-Pablo3, Javier Loricera3, M. Victoria Hernández4, Alfredo Adan5, Marina Mesquida5, Diana Peiteado6, David Diaz-Valle7, Lucía Martínez-Costa8, Elia Valls-Pascual8, Miguel A. Caracuel9, Angel Garcia-Aparicio10, Jose M Herreras11, Miguel Cordero-Coma12, Carlos Alberto Montilla-Morales13, Alejandro Fonollosa14, Antonio Atanes15, Félix Francisco16, Ignacio Torre-Salaberri17, Olga Maíz18, Ana Blanco19, Cruz Fernandez-Espartero20, Norberto Ortego Centeno21, Enrique Raya Álvarez22, Myriam Gandía23, Francisco Javier López Longo24, Maria Alcalde-Villar25, Cristina Fernández-Carballido26, Esperanza Pato Cour27, Oscar Ruiz Moreno28, Fernando Jiménez-Zorzo29, Raquel Almodóvar González30, Carmen Carrasco-Cubero31, Luis Francisco Linares32, Fredeswinda I. Romero-Bueno33, Santos Insua34, Senen González-Suárez35, Marisa Hernández36, Emma Beltrán37, Juan Cruz38, Carlos Férnandez Cid39, Elena Aurrecoechea40, Enar Pons1, Miguel Angel González-Gay3 and Ricardo Blanco1, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 2Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 3Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 4Rheumatology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, 5Hospital Clinic. Barcelona. Spain, Barcelona, Spain, 6Rheumatology, Rheumatology, La Paz University Hospital, Madrid, Spain, 7Hospital Clínico San Carlos. Madrid. Spain, Madrid, Spain, 8Hospital Universitario Doctor Peset. Valencia. Spain, Valencia, Spain, 9Hospital de Córdoba, Córdoba, Spain., Córdoba, Spain, 10Rheumatology, Hospital de Toledo. Toledo. Spain, Toledo, Spain, 11Ophthalmology, Hospital Universitario, IOBA. Valladolid. Spain, Valladolid, Spain, 12Ophthalmology, Hospital de León. Spain, León, Spain, 13Hospital Clínico Universitario de Salamanca. Spain, Salamanca, Spain, 14Ophthalmology, Hospital de Cruces. Bilbao. Spain, Bilbao, Spain, 15Complejo Hospitalario Universitario A Coruña. Spain, A Coruna, Spain, 16Rheumatology, Hospital Doctor Negrín. Las Palmas de Gran Canaria. Spain, Las Palmas de Gran Canaria, Spain, 17Rheumatology, Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, 18Hospital Universitario Donostia. San Sebastian. Spain, San Sebastián, Spain, 19Ophtamology, Hospital Universitario Donostia. San Sebastian. Spain, San Sebastian, Spain, 20Rheumatology, Hospital de Móstoles. Madrid. Spain, Madrid, Spain, 21Medicine Department, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, 22Rheumatology, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, 23Rheumatology, Hospital Puerta del Mar. Cádiz. Spain, Cádiz, Spain, 24Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain, 25Hospital Severo Ochoa, Madrid, Spain, Madrid, Spain, 26Rheumatology Division, Hospital General Universitario de Elda, Elda, Spain, 27Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, 28Ophthalmology and Rheumatology, Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, 29Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, 30Rheumatology, Hospital Universitario Fundación Alcorcón. Madrid. Spain, Madrid, Spain, 31Hospital de Mérida. Spain, Mérida, Spain, 32Rheumatology, Hospital Virgen de la Arrixaca. Murcia. Spain, Murcia, Spain, 33Section for Autoimmune Diseases, Rheumatology, Fundación Jiménez Díaz University Hospital & Health Research Institute, Madrid, Spain, 34Rheumatology, Hospital Universitario Santiago de Compostela. La Coruña. Spain, La Coruña, Spain, 35Rheumatology, Hospital de Cabueñes. Gijón. Spain, Gijón, Spain, 36Ophthalmology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, 37Rheumatology, Hospital del Mar. Barcelona. Spain, Barcelona, Spain, 38Hospital de Pontevedra. Pontevedra. Spain, Pontevedra, Spain, 39Ophthalmology, Hospital de Pontevedra. Pontevedra. Spain, Pontevedra, Spain, 40Rheumatology, Hospital de Sierrallana, Torrelavega. Cantabria. Spain, Torrelavega, Spain

    Background/Purpose: Retinal vasculitis is a serious complication of uveitis due to Behçet’s disease (BD). The treatment is based on corticosteroids, conventional immunosuppressants (IS) and anti-TNF-α…
  • Abstract Number: 1767 • 2017 ACR/ARHP Annual Meeting

    The Effect on Health-Related Quality of Life of Treatment for Remission Maintenance in ANCA-Associated Vasculitis Beyond 18 Months

    Gunnar Tomasson1, Antoine G. Sreih2, David Cuthbertson3, Simon Carette4, Nader A. Khalidi5, Curry L. Koening6, Carol A. Langford7, Carol A. McAlear8, Paul A. Monach9, Larry W. Moreland10, Philip Seo11, Ulrich Specks12, Steven R. Ytterberg13 and Peter A. Merkel14, 1University of Iceland, Faculty of Medicine, Reykjavik, IS, 2Rheumatology, University of Pennsylvania, Philadelphia, PA, 3Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, 4Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 5Rheumatology, McMaster University, Hamilton, ON, Canada, 6Rheumatology, University of Utah, Salt Lake City, UT, 7Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, 8University of Pennsylvania, Philadelphia, PA, 9Boston University School of Medicine, Boston, MA, 10Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 11Medicine, Johns Hopkins University, Baltimore, MD, 12Mayo Clinic College of Medicine, Rochester, MN, 13Rheumatology, Mayo Clinic, Rochester, MN, 14Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Standard management of ANCA-associated vasculitis (AAV) involves treatment with immunosuppressive agents for at least 18 months.  Treatment beyond 18 months reduces the rates of…
  • Abstract Number: 1776 • 2017 ACR/ARHP Annual Meeting

    Adverse Events for Discontinuation of Immunosuppressants and Outcome of Their Re-Administration in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Single Center Study in Japan

    Takamasa Murosaki, Takeo Sato, Yoichiro Akiyama, Katsuya Nagatani and Seiji Minota, Department of Internal Medicine, Division of Rheumatology/Clinical Immunology, Jichi Medical University, Shimotsuke, Japan

    Background/Purpose: The combination of immunosuppressants and glucocorticoid is recommended for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). However, adverse events of immunosuppressants sometimes…
  • Abstract Number: 2028 • 2017 ACR/ARHP Annual Meeting

    Compliance with Pneumococcal Vaccination in Rheumatic Disease Patients on Immunosuppressive Medications

    Zainab Shahnawaz1, Fatme Allam2 and Andras Perl3, 1Medicine/Rheumatology, SUNY Upstate Medical University, Syracuse, NY, 2SUNY Upstate Medical University, Syracuse, NY, 3Medicine, SUNY Upstate Medical University, Syracuse, NY

    Background/Purpose: The 2012 recommendations of the Centers for Disease Control (CDC) advise that adults aged ≥19 years with immunocompromising conditions including patients on iatrogenic immunosuppression…
  • Abstract Number: 2139 • 2017 ACR/ARHP Annual Meeting

    Analysis of Required Dose of Corticosteroid As Maintenance Therapy and Related Factors in Patients with Polymyositis/Dermatomyositis

    Eri Watanabe1, Takahisa gono1, Shinji Watanabe1, Hiroki Yabe1, Masataka Kuwana2 and Chihiro Terai1, 1Department of Rheumatology, Saitama Medical Center, Jichi Medical University, Saitama, Japan, 2Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan

    Background/Purpose: PM and DM are inflammatory myopathies, sometimes complicated by interstitial lung disease (ILD), myocarditis, arthritis, and malignancies. The intensity of immunosuppressive therapies depends on…
  • Abstract Number: 2624 • 2017 ACR/ARHP Annual Meeting

    A Renal Biopsy Should Not Delay Treatment Initiation in Suspected Lupus Nephritis

    Astrid Baumann1, Angela Pakozdi2, Andrea Cove-Smith2, Debasish Pyne2, Michael Sheaff1 and Ravindra Rajakariar2, 1Barts Lupus Centre, London, United Kingdom, 2Barts Lupus Centre, Barts Health NHS Trust, London, United Kingdom

    Background/Purpose: Renal biopsies are considered the gold standard in diagnosing lupus nephritis (LN). ALMS (1), the largest randomized trial in LN, reported the non-inferiority of…
  • Abstract Number: 2738 • 2017 ACR/ARHP Annual Meeting

    Infectious Complications in Systemic Necrotizing Vasculitides: Pooled Analysis of Five Prospective, Randomized, Controlled Trials

    Lafarge Antoine1, Christian Pagnoux2, Xavier Puéchal3, Maxime Samson4, Mohamed Hamidou5, Alexandre Karras6, Thomas Quémeneur7, Matthieu Groh8, Luc Mouthon9, Loïc Guillevin for the French Vasculitis Study Group3 and Benjamin Terrier10, 1Medecine Interne, Hôpital Cochin, Paris, France, 2Mount Sinai Hospital, Toronto, ON, Canada, 3Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France, 4Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, 5Medecine Interne, CHU Hôtel Dieu, Nantes, France, 6nephrology, HEGP, Paris, France, 7Service de néphrologie, médecine interne et vasculaire, Hôpital de Valenciennes, Valenciennes, France, 8National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, 9Université Paris Descartes Sorbonne Paris, Paris, France, 10Internal Medicine, Cochin University Hospital, Paris, France

    Background/Purpose: Prognosis of patients with systemic necrotizing vasculitides has been markedly improved during the last 2 decades. However, infectious complications remain a major cause of…
  • Abstract Number: 2739 • 2017 ACR/ARHP Annual Meeting

    Onco-Hematological Malignancies in Systemic Necrotizing Vasculitides: Pooled Analysis of Five Prospective, Randomized, Controlled Trials

    Lafarge Antoine1, Christian Pagnoux2, Xavier Puéchal3, Maxime Samson4, Mohamed Hamidou5, Alexandre Karras6, Thomas Quémeneur7, Matthieu Groh8, Luc Mouthon9, Loïc Guillevin for the French Vasculitis Study Group3 and Benjamin Terrier10, 1Medecine Interne, Hôpital Cochin, Paris, France, 2Mount Sinai Hospital, Toronto, ON, Canada, 3Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France, 4Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, 5Medecine Interne, CHU Hôtel Dieu, Nantes, France, 6nephrology, HEGP, Paris, France, 7Service de néphrologie, médecine interne et vasculaire, Hôpital de Valenciennes, Valenciennes, France, 8National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, 9Université Paris Descartes Sorbonne Paris, Paris, France, 10Internal Medicine, Cochin University Hospital, Paris, France

    Background/Purpose: The use of long-term immunosuppressive agents in patients with systemic necrotizing vasculitides has dramatically improved the overall prognosis, but expose patients to potential severe…
  • Abstract Number: 1099 • 2017 ACR/ARHP Annual Meeting

    Hepatitis B Reactivation in Rheumatologic Patients

    Yassir Daghistani1, Fergus To2, Patrick Doyle3,4, Hin Hin Ko5, Mel Krajden3,4, Jason Kur2, Alnoor Ramji6, Kam Shojania2, Edward Tam5, John Wade2, Eric Yoshida5, Graham Reid2, Siegfried Erb5 and Mollie Carruthers2, 1Medicine, University of British Columbia, Vancouver, BC, Canada, 2Rheumatology, University of British Columbia, Vancouver, BC, Canada, 3Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada, 4BC Centre for Disease Control, Vancouver, BC, Canada, 5Gastroenterology, University of British Columbia, Vancouver, BC, Canada, 6Gatroenterology, University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: The widespread usage of biologic disease modifying anti-rheumatic drugs (bDMARDs) in rheumatology has increased the risk of hepatitis B virus (HBV) re-activation. The prevalence…
  • Abstract Number: 425 • 2016 ACR/ARHP Annual Meeting

    Improving Pneumococcal Vaccination Rates for Immunosuppressed Patients in an Academic Rheumatology Clinic

    Alison Bays1, Renuka R. Nayak2, Sara Murray3, Darlene Young4, Gabriela Schmajuk5, Jinoos Yazdany6 and Andrew Gross7, 1Rheumatology, University of Washington, Seattle, WA, 2Rheumatology, UCSF, San Francisco, CA, 3Medicine, UCSF, San Francisco, CA, 4Medicine/Rheumatology, UCSF, San Francisco, CA, 5San Francisco VA Medical Center, University of California, San Francisco, San Francisco, CA, 6Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 7Medicine/Rheumatology, University of California San Francisco, San Francisco, CA

    Background/Purpose: Patients with autoimmune conditions have higher rates of  pneumococcal disease and they are often immunosuppressed. In 2014, the Advisory Committee on Immunization Practices issued…
  • Abstract Number: 831 • 2016 ACR/ARHP Annual Meeting

    Immunosuppression May Prevent Interstitial Lung Disease in Systemic Sclerosis

    Sabrina Hoa1, Marie Hudson2, Mianbo Wang3, Russell Steele4, Murray Baron5 and Canadian Scleroderma Research Group, 1Division of Rheumatology, Jewish General Hospital, Lady Davis Institute, Montreal, QC, Canada, 2Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, QC, Canada, 3Lady Davis Institute for Medical Research, Montreal, QC, Canada, 4Mathematics, McGill University, Montreal, QC, Canada, 5Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada

    Background/Purpose: Interstitial lung disease (ILD) is a leading cause of premature mortality in systemic sclerosis (SSc). Immunosuppression is used for treatment of established disease. However,…
  • Abstract Number: 839 • 2016 ACR/ARHP Annual Meeting

    Immunosuppression Does Not Prevent Severe Gastrointestinal Disease in Systemic Sclerosis

    Nicolas Richard1, Marie Hudson2, Mianbo Wang3, Murray Baron4, Genevieve Gyger1 and Canadian Scleroderma Research Group, 1McGill University, Jewish General Hospital, Montreal, QC, Canada, 2Medicine/Rheumatology, Jewish General Hospital, Lady Davis Research Institute, Montreal, QC, Canada, 3Lady Davis Institute for Medical Research, Montreal, QC, Canada, 4Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada

    Background/Purpose: Severe gastrointestinal (GI) disease is associated with considerable morbidity and high mortality in systemic sclerosis (SSc). There are no known preventative treatments. We wished…
  • Abstract Number: 845 • 2016 ACR/ARHP Annual Meeting

    Current Use of Off-Label Therapies in Systemic Sclerosis-Associated Interstitial Lung Disease

    Elise Siegert1, Dörte Huscher2, Ulf Müller-Ladner3, Veronika K. Jaeger4, Ulrich A. Walker4, Marc Frerix5, László Czirják6, Francesco Del Galdo7, Gabriele Valentini8, Marco Matucci-Cerinic9, Yannick Allanore10, Oliver Distler11, Christopher Denton12, Gabriela Riemekasten13 and EUSTAR co-authors, 1Rheumatology and Clinical Immunology, Charité – University Medicine Berlin, Berlin, Germany, 2Epidemiology, German Rheumatism Research Centre, Berlin, Germany, 3Department of Internal Medicine and Rheumatology, Justus-Liebig-University Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany, 4Department of Rheumatology, University Hospital Basel, Basel, Switzerland, 5Department of Rheumatology and Clinical Immunology, Justus-Liebig-University Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany, 6Department of Rheumatology and Immunology, University of Pécs, Faculty of Medicine, Pécs, Hungary, 7Musculoskeletal Diseases, Scleroderma Research Program, Leeds Institute of Molecular Medicine, Division of Musculoskeletal Diseases, University of Leeds, Leeds, United Kingdom, 8Internal and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy, 9Department of Medicine, Division of Rheumatology, University of Florence, Florence, Italy, 10Rheumatology, Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, 11Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 12Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, 13Department of Rheumatology, Universitatsklinikum Schleswig-Holstein, Lubeck, Germany

    Background/Purpose: Systemic Sclerosis (SSc) is a connective tissue disease that is often complicated by secondary interstitial lung disease (SSc-ILD). Due to its high morbidity and…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology